dc.contributor.author |
Billington, Emma O |
|
dc.contributor.author |
Reid, Ian R |
|
dc.date.accessioned |
2020-12-08T02:11:36Z |
|
dc.date.available |
2020-12-08T02:11:36Z |
|
dc.date.issued |
2020-10 |
|
dc.identifier.issn |
1544-1873 |
|
dc.identifier.uri |
http://hdl.handle.net/2292/53815 |
|
dc.description.abstract |
PURPOSE OF REVIEW:Recent evidence from clinical trials and observational studies raises the possibility that bisphosphonate use might confer a lower risk of cardiovascular disease and cancer, resulting in a mortality benefit. This review summarizes clinical and preclinical studies examining the non-skeletal effects of bisphosphonates. RECENT FINDINGS:Data from clinical trials are conflicting regarding whether or not bisphosphonates have beneficial effects on mortality, cardiovascular events, or cancer incidence. No clinical trials have assessed these outcomes as primary endpoints, and most trials were shorter than 4 years. Observational data suggest that bisphosphonate users may have lower mortality, delayed progression of vascular calcification and atherosclerotic burden, and reduced incidence of breast and colorectal cancer compared to non-users. Preclinical studies confirm that bisphosphonates can be taken up by macrophages and monocytes, and nitrogen-containing bisphosphonates have the ability to disrupt the mevalonate pathway within these cells. In this manner, bisphosphonates exert anti-atherogenic and anti-cancer effects. Bisphosphonates also appear to exert protective effects on vascular smooth muscle cells and endothelial cells and may have direct cytotoxic effects on cancer cells. The balance of evidence does not support bisphosphonate treatment for the primary purpose of improving non-skeletal outcomes, although appropriately designed controlled trials that further explore this possibility are both justified and required. Patients with skeletal indications for bisphosphonate therapy can be reassured that these agents are not associated with increased mortality, cardiovascular disease, or cancer incidence. |
|
dc.format.medium |
Print |
|
dc.language |
eng |
|
dc.publisher |
Springer Science and Business Media LLC |
|
dc.relation.ispartofseries |
Current osteoporosis reports |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Endocrinology & Metabolism |
|
dc.subject |
Bisphosphonates |
|
dc.subject |
Zoledronic acid |
|
dc.subject |
Mortality |
|
dc.subject |
Cardiovascular disease |
|
dc.subject |
Cancer |
|
dc.subject |
Osteoporosis |
|
dc.subject |
INTIMA-MEDIA THICKNESS |
|
dc.subject |
ZOLEDRONIC ACID |
|
dc.subject |
BREAST-CANCER |
|
dc.subject |
COLORECTAL-CANCER |
|
dc.subject |
INTRAVENOUS ZOLEDRONATE |
|
dc.subject |
ENDOTHELIAL FUNCTION |
|
dc.subject |
CLINICAL FRACTURES |
|
dc.subject |
PROSTATE-CANCER |
|
dc.subject |
BONE LOSS |
|
dc.subject |
RISK |
|
dc.subject |
1102 Cardiorespiratory Medicine and Haematology |
|
dc.subject |
Clinical |
|
dc.subject |
Clinical Medicine and Science |
|
dc.subject |
Cancer |
|
dc.subject |
Clinical Trials and Supportive Activities |
|
dc.subject |
Clinical Research |
|
dc.subject |
Cardiovascular |
|
dc.subject |
Cardiovascular |
|
dc.subject |
Cancer |
|
dc.subject |
6.1 Pharmaceuticals |
|
dc.subject |
2.1 Biological and endogenous factors |
|
dc.subject |
1103 Clinical Sciences |
|
dc.subject |
1117 Public Health and Health Services |
|
dc.title |
Benefits of Bisphosphonate Therapy: Beyond the Skeleton. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1007/s11914-020-00612-4 |
|
pubs.issue |
5 |
|
pubs.begin-page |
587 |
|
pubs.volume |
18 |
|
dc.date.updated |
2020-11-19T02:50:31Z |
|
dc.rights.holder |
Copyright: The author |
en |
pubs.author-url |
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000559297500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=6e41486220adb198d0efde5a3b153e7d |
|
pubs.end-page |
596 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Review |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
810219 |
|
dc.identifier.eissn |
1544-2241 |
|
pubs.online-publication-date |
2020-7-31 |
|